Skip to content

Study · Observational study · n = 100 · 2020

8 results

Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?

Moreno-Fernandez J, Garcia-Seco JA, Seco Segura AM, Garcia-Seco F, Rozas Moreno PJ, Aguirre Sanchez-Covisa M

Primary care diabetes4 Jun 2019Cited by 6 (Europe PMC)

PMID31171461 (opens in a new tab)DOI10.1016/j.pcd.2019.05.006 (opens in a new tab)PepBankPUB-31171461
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, final HbA1c did not differ between liraglutide and lixisenatide.

    In plain wordsIn obese adults with type 2 diabetes, final HbA1c was similar with liraglutide and lixisenatide.

    Peptide
    Liraglutide
    Outcome
    No significant changeFinal HbA1c
    Study

    n = 100

    Comparator
    Lixisenatide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Final HbA1c
    7.3%
    liraglutide
    Final HbA1c
    7.2%
    lixisenatide

    Source sentences

    Summary
    No differences were found in final HbA1c values between both groups (liraglutide 7.3 ± 0.9% vs. lixisenatide 7.2 ± 1.5%, P = 0.7).
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  2. 02HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, anthropometric variables did not differ between liraglutide and lixisenatide at study end.

    In plain wordsIn obese adults with type 2 diabetes, body measures were similar with liraglutide and lixisenatide at study end.

    Peptide
    Liraglutide
    Outcome
    No significant changeAnthropometric variables
    Study

    n = 100

    Comparator
    Lixisenatide
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    We did not detect between groups differences in anthropometric variables or CVRF at the study end.
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  3. 03HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, cardiovascular risk factors did not differ between liraglutide and lixisenatide at study end.

    In plain wordsIn obese adults with type 2 diabetes, heart risk factors were similar with liraglutide and lixisenatide at study end.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiovascular risk factors
    Study

    n = 100

    Comparator
    Lixisenatide
    Analysis
    Secondary
    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    We did not detect between groups differences in anthropometric variables or CVRF at the study end.
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  4. 04HumanObservational studyOther

    In obese adults with type 2 diabetes, fewer liraglutide-treated patients than lixisenatide-treated patients intensified treatment by adding SGLT2 inhibitors.

    In plain wordsIn obese adults with type 2 diabetes, fewer patients on liraglutide than on lixisenatide needed an added SGLT2 inhibitor.

    Peptide
    Liraglutide
    Outcome
    DecreaseTreatment intensification with SGLT2 inhibitors
    Study

    n = 100

    Comparator
    Lixisenatide
    Analysis
    Secondary
    Outcome group
    Patterns of use · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    SGLT2 inhibitor added
    9%
    liraglutide
    SGLT2 inhibitor added
    29%
    lixisenatide

    Source sentences

    Summary
    In contrast, a greater percentage of patients in the lixisenatide group than in liraglutide group (29% vs. 9%, P = 0.026) intensified treatment by the addition of sodium-glucose transporter type 2 inhibitors.
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  5. 05HumanObservational studyOther

    In obese adults with type 2 diabetes, a lower proportion of patients received the maximum dose of liraglutide than of lixisenatide.

    In plain wordsIn obese adults with type 2 diabetes, fewer patients reached the top dose of liraglutide than of lixisenatide.

    Peptide
    Liraglutide
    Outcome
    DecreasePatients on maximum dose
    Study

    n = 100

    Comparator
    Lixisenatide
    Outcome group
    Patterns of use · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Maximum dose proportion
    27%
    liraglutide
    Maximum dose proportion
    95%
    lixisenatide

    Source sentences

    Summary
    A lower proportion of patients received treatment with a maximum dose of liraglutide compared with lixisenatide (27% vs. 95%, P < 0.001).
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  6. 06HumanObservational studySafety outcome

    In obese adults with type 2 diabetes, adverse events were reported less often with liraglutide than with lixisenatide.

    In plain wordsIn obese adults with type 2 diabetes, side effects were reported less often with liraglutide than with lixisenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAdverse events
    Study

    n = 100

    Comparator
    Lixisenatide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Adverse events
    80%
    liraglutide
    Adverse events
    96%
    lixisenatide

    Source sentences

    Summary
    Adverse events were less frequently reported in liraglutide treated patients compared with lixisentatide (80% vs. 96%, P = 0.014).
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  7. 07HumanObservational studySafety outcome

    In obese adults with type 2 diabetes, no serious adverse events were detected.

    In plain wordsIn obese adults with type 2 diabetes, no serious adverse events were detected.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious adverse events
    Study

    n = 100

    Comparator
    Lixisenatide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No serious adverse events were detected.
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.
  8. 08HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes, HbA1c fell by 1.4% with liraglutide over 24 weeks.

    In plain wordsIn obese adults with type 2 diabetes, HbA1c fell with liraglutide over 24 weeks in routine care.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 50

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.4%
    liraglutide

    Source sentences

    Summary
    Both groups experienced a decrease in HbA1c values (liraglutide, -1.4%, CI 95% -2, -0.8, P < 0.001
    2 context sentences
    Summary · context
    A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice.
    Summary · context
    A total of 100 patients (50 liraglutide, 50 lixisenatide) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.